Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virginia narrow therapeutics bill refers decision on substitutions to state pharmacy board.

Executive Summary

NARROW THERAPEUTICS INDEX DECISION TO BE REFERRED TO VIRGINIA PHARMACY BOARD, under legislation passed 35-4 with one abstention by the Virginia Senate Feb. 20. HB 2736 was introduced by Jay DeBoer (D), who represents Virginia's 63rd district, where Merck facilities are located. DuPont Merck has been a prominent supporter of measures restricting substitution of generics for brand name products, since its anticoagulant product Coumadin (warfarin) is facing generic competition in the near future.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel